IL292704A - Methods of treatment with antibodies against bcma and cd3 - Google Patents

Methods of treatment with antibodies against bcma and cd3

Info

Publication number
IL292704A
IL292704A IL292704A IL29270422A IL292704A IL 292704 A IL292704 A IL 292704A IL 292704 A IL292704 A IL 292704A IL 29270422 A IL29270422 A IL 29270422A IL 292704 A IL292704 A IL 292704A
Authority
IL
Israel
Prior art keywords
bispecific antibody
dose
maintenance dose
use according
maintenance
Prior art date
Application number
IL292704A
Other languages
English (en)
Hebrew (he)
Inventor
Burgess Michael
Hege Kristen
Datta Kaushik
BOSS Isaac
Diem VU Minh
Original Assignee
Bristol Myers Squibb Co
Burgess Michael
Hege Kristen
Datta Kaushik
BOSS Isaac
Diem VU Minh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Burgess Michael, Hege Kristen, Datta Kaushik, BOSS Isaac, Diem VU Minh filed Critical Bristol Myers Squibb Co
Publication of IL292704A publication Critical patent/IL292704A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL292704A 2019-11-05 2020-11-04 Methods of treatment with antibodies against bcma and cd3 IL292704A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19207293 2019-11-05
EP20179573 2020-06-11
PCT/US2020/058939 WO2021092056A1 (en) 2019-11-05 2020-11-04 Methods of treatment with antibodies against bcma and cd3

Publications (1)

Publication Number Publication Date
IL292704A true IL292704A (en) 2022-07-01

Family

ID=75849140

Family Applications (1)

Application Number Title Priority Date Filing Date
IL292704A IL292704A (en) 2019-11-05 2020-11-04 Methods of treatment with antibodies against bcma and cd3

Country Status (11)

Country Link
US (1) US20230057602A1 (enExample)
EP (1) EP4054725A4 (enExample)
JP (1) JP7792333B2 (enExample)
KR (1) KR20220093141A (enExample)
CN (1) CN115279459A (enExample)
AU (1) AU2020379757A1 (enExample)
BR (1) BR112022008516A2 (enExample)
CA (1) CA3160137A1 (enExample)
IL (1) IL292704A (enExample)
MX (1) MX2022005292A (enExample)
WO (1) WO2021092056A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2963692A1 (en) 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1
KR102745676B1 (ko) 2016-12-21 2024-12-24 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
SI3819007T1 (sl) 2019-11-11 2024-10-30 Amgen Inc. Režim odmerjanja sredstev proti BCMA
CN119569887A (zh) * 2021-06-24 2025-03-07 益科思特(北京)医药科技发展有限公司 结合bcma和cd3的双特异性抗体及其制备方法与应用
WO2025042742A1 (en) * 2023-08-18 2025-02-27 Bristol-Myers Squibb Company Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
WO2025059362A1 (en) 2023-09-13 2025-03-20 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025117764A1 (en) * 2023-12-01 2025-06-05 Teneoone, Inc. Methods for the treatment of multiple myeloma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2738568C (en) * 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
EP2762497A1 (en) * 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
AU2016302881B2 (en) * 2015-08-03 2022-09-15 Bristol-Myers Squibb Company Monoclonal antibodies against BCMA
EP3535295A1 (en) * 2016-11-02 2019-09-11 EngMab Sàrl Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
KR20190074300A (ko) * 2016-11-15 2019-06-27 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약

Also Published As

Publication number Publication date
AU2020379757A1 (en) 2022-05-26
US20230057602A1 (en) 2023-02-23
WO2021092056A1 (en) 2021-05-14
JP7792333B2 (ja) 2025-12-25
EP4054725A1 (en) 2022-09-14
KR20220093141A (ko) 2022-07-05
CA3160137A1 (en) 2021-05-14
CN115279459A (zh) 2022-11-01
MX2022005292A (es) 2022-08-10
EP4054725A4 (en) 2024-01-10
JP2022553822A (ja) 2022-12-26
BR112022008516A2 (pt) 2022-08-30

Similar Documents

Publication Publication Date Title
JP2022553822A5 (enExample)
US8568721B2 (en) Method of treating rheumatoid arthritis with an anti-IL-6R antibody
JP3616091B2 (ja) 自己免疫疾患および炎症性疾患の治療
CA2261630C (en) Anti-tnf antibodies and methotrexate in the treatment of autoimmune disease
JP2018537962A5 (enExample)
KR20220007593A (ko) 암 치료에서의 효능 강화를 위한 pd-1 억제제와 lag-3 억제제의 병용
US11851485B2 (en) Engineered anti-IL-2 antibodies
JP7792333B2 (ja) Ｂｃｍａおよびｃｄ３に対する抗体を用いる処置方法
WO2021068196A1 (en) Methods of using il-33 protein in treating cancers
EP3827021A1 (en) Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use
JP7783183B2 (ja) 自己免疫障害における抗ｂｃｍａ治療
US20220213203A1 (en) Dosing Regimens of Bispecific CD123 x CD3 Diabodies in the Treatment of Hematologic Malignancies
CN106573059A (zh) 接受过抗TNF‑α抗体疗法的银屑病患者的治疗方法
Ochi et al. Bispecific antibodies for multiple myeloma: past, present and future
Sckisel et al. Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy
WO2024192033A1 (en) Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating melanoma
US20230172923A1 (en) Methods of treating cytokine-related adverse events
TW202302642A (zh) 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
US20250152710A1 (en) Modified primary immune cells for induction or enhancement of immunotherapy
JP2025508832A (ja) サイトカイン放出症候群の軽減のための投与レジメン
CN121712524A (zh) 包含结合bcma和cd3的抗体的组合物以及治疗方法
JP2025508832A5 (enExample)
CN120152730A (zh) 用于在治疗癌症的方法中使用的重组il-12白蛋白结合结构域融合蛋白
EA049485B1 (ru) Комбинация ингибиторов pd-1 и ингибиторов lag-3 для повышения эффективности при лечении рака
RU2024117373A (ru) Антитело к рецептору il-6 для лечения ювенильного идиопатического артрита